The Food and Drug Administration (FDA) today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma and venous or fingerstick whole blood specimens. Approved for use as an aid in the diagnosis of HIV-1 and HIV-2 infection, the Alere Determine HIV-1/2 Ag/Ab Combo test is also the first FDA-approved test that independently distinguishes results for HIV-1 p24 antigen and HIV antibodies in a single test.
The test can be used by trained professionals in outreach settings to identify HIV-infected individuals who might not be able to be tested in traditional health care settings. The test does not distinguish between antibodies to HIV-1 and HIV-2, and is not intended to be used for screening of blood donors.
Detection of HIV-1 antigen permits earlier detection of HIV-1 infection than is possible by testing for HIV-1 antibodies alone. The test, can distinguish acute HIV-1 infection from established HIV-1 infection when the blood specimen is positive for HIV-1 p24 antigen but is negative for HIV-1 and HIV-2 antibodies.
“This test helps diagnose HIV infection at an earlier time in outreach settings, allowing individuals to seek medical care sooner,” says Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research. “Earlier diagnosis may also help to reduce additional HIV transmission.”
HIV infection can result in the development of Acquired Immune Deficiency Syndrome, or AIDS. HIV damages the body’s defense mechanisms by destroying specific blood cells, called CD4+ T cells, which are crucial to helping the body fight diseases. Two types of HIV have been identified, HIV-1 and HIV-2. HIV-1 is responsible for most HIV infections throughout the world. HIV-2 is found primarily in West Africa; however, cases of HIV-2 infection have been reported in North America and Europe.
The Centers for Disease Control and Prevention (CDC) estimates that each year approximately 50,000 people are infected with HIV in the United States. Of the more than 1 million people living with HIV in the United States, approximately 20 percent of those people have not been diagnosed.
The Alere Determine HIV-1/2 Ag/Ab Combo test is manufactured by Orgenics, Ltd. (an Alere, Inc. company) of Yavne, Israel.
FDA Approves First Rapid Diagnostic Test to Detect HIV-1 Antigen and HIV-1/2 Antibodies
Posted in News, Food And Drug Administration (FDA), Rapid Diagnostics, Hiv Infection, Human Immunodeficiency Virus (HIV), Antibodies, Antigens
- FDA Approves First Genotyping Test for Patients with Hepatitis C Virus
- CDC Addresses Recurrent Nationwide Shortage of Tuberculin Skin Test Antigen Solutions
- Rapid Diagnostic Tests Decrease Waiting Time for Drug-Resistant TB Patients
- FDA Approves New Drug to Treat HIV Infection
- FDA Approves Vibativ for Hospitalized Patients with Bacterial Pneumonia
- In Mouse Model, Wolfberries Show Reduced Risk for Flu Virus When Combined with Vaccine
- Researchers Discover Common Cell Wall Component in Chlamydia Bacteria
- New Way to Fight Antibiotic-Resistant Bacteria: Target Human Cells Instead
- Experts Say Guidelines on Antibiotics Fail to Protect Public Health
- FDA Takes Steps to Address Antimicrobial Resistance